Introduction

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among individuals over the age of 50. As the global population ages, the prevalence of AMD is expected to rise, placing an increasing burden on healthcare systems. Traditional treatments for AMD have shown limited success, but recent research points to a promising new approach: light therapy, including photodynamic therapy (PDT) and photobiomodulation (PBM). In this article, we delve into the science behind these therapies and their potential to revolutionize AMD treatment.

Fig.1 Age-related macular degeneration

(https://corkeyeclinic.ie/page/art/648/0)

 

Photodynamic Therapy (PDT): Targeting Abnormal Blood Vessels

Photodynamic therapy is a well-established treatment for the wet form of AMD, where abnormal blood vessels grow beneath the retina, leading to leakage and vision loss. The treatment involves the injection of a light-sensitive drug into a vein, followed by the application of a low-level laser to activate the drug. This activation causes the drug to create blood clots in the abnormal blood vessels, effectively sealing them off and preventing further leakage^[1].

While PDT has been successful in stabilizing vision in some patients, its effects are often short-lived as the abnormal blood vessels may reopen. Moreover, PDT does not restore lost vision, only slows the rate of further damage. However, advancements in drug therapy have expanded treatment options, making PDT a complementary approach in managing wet AMD.

Fig.2 PDT for Wet AMD

(https://www.wkhs.com/health-resources/wk-health-library/medical-procedures-tests-care-and-management/a-z/photodynamic-therapy-%28pdt%29-for-wet-amd)

Photobiomodulation (PBM): Recharging the Retinal Energy System

A more recent development in AMD treatment is PBM, which utilizes red to near-infrared light to stimulate cellular processes. PBM targets the mitochondria in retinal cells, the cellular structures responsible for energy production. With age, mitochondrial function declines, reducing the energy available for retinal cells and contributing to AMD progression^[2].

Research suggests that PBM can improve mitochondrial function, reduce oxidative stress, and modulate inflammatory pathways, all of which are implicated in AMD. In a study by the University College London, participants exposed to deep red light showed significant improvements in color contrast sensitivity, a common deficit in AMD^[3]. The therapy's potential is underscored by the LIGHTSITE III clinical trial, which indicated that PBM slowed the progression of dry AMD to late-stage disease^[4].

Light wavelength

The choice of light wavelength in PBM is critical, as different wavelengths penetrate tissue to different depths. Red light (670nm) has been shown to enhance mitochondrial function and ATP production, while near-infrared light (830 nm) can reach deeper into the retina, potentially affecting a broader range of cellular processes^[5]. Multi-wavelength PBM may offer the advantage of targeting multiple cellular pathways simultaneously, thereby improving cellular function and potentially slowing the progression of AMD^[6], increasing the therapy's efficacy.

Fig 3. Wavelengths of red light

(https://platinumtherapylights.com/blogs/news/red-vs-infrared-and-nir-light-therapy)

Safety and Tolerability

Both PDT and PBM are generally well-tolerated, with few side effects. However, patients should be cautious of devices claiming to offer red light therapy, as it is not yet an approved treatment for AMD, and the U.S. Food and Drug Administration has not evaluated its safety and efficacy^[5]. It is crucial for patients to consult with eye care professionals before starting any new therapy.

The Future of Light Therapy for AMD

The potential for light therapy to slow or even halt the progression of AMD is exciting. As research continues, we may see light therapy become a mainstream treatment option for AMD, offering hope to millions affected by this condition. With ongoing clinical trials and technological advancements, the future looks bright for those living with AMD.

Conclusion

The advent of light therapy offers a non-invasive and potentially transformative approach to managing AMD. By harnessing the power of red and near-infrared light, we may be able to slow the progression of this debilitating condition, improving the lives of millions. As we stand on the cusp of a new era in ophthalmology, the prospect of light therapy becoming a cornerstone of AMD treatment is an exciting development that clinicians and patients alike will be watching closely.

References

1. "Photodynamic Therapy for Age-Related Macular Degeneration." Johns Hopkins Medicine. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/photodynamic-therapy-for-agerelated-macular-degeneration

2. Henein, C., & Steel, D. H. W. (2021). Photobiomodulation for non-exudative age-related macular degeneration. Cochrane Database of Systematic Reviews, 2021, Issue 5. Art. No.: CD013029. DOI: 10.1002/14651858.CD013029.pub2.

3. "What You Should Know About Using Red Light Therapy for Ocular Conditions." UCHealth. https://news.cuanschutz.edu/ophthalmology/what-you-should-know-about-using-red-light-therapy-for-ocular-conditions

4. "Are we a step closer to treating AMD with red light?" Macular Society. https://www.macularsociety.org/about/media/news/2023/september/are-we-a-step-closer-to-treating-amd-with-red-light/

5. "Red Light Therapy Could Improve Age-Related Vision Decline." Allied Eye. https://www.alliedeye.com/blog/redlighttherapy.

6. "Red Light Therapy for Macular Degeneration." Healthline. Available at: https://www.healthline.com/health/eye-health/red-light-therapy-for-macular-degeneration (accessed on December 10, 2023).